Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 5/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10457502 | 0.82 | TRPA1 (0.40) | TRPA1MAPTALOX15CYP3A4ESR1 | |
| SCHEMBL11246743 | 0.81 | TRPA1 (0.40) | TRPA1MAPTALOX15GAAESR1 | |
| SCHEMBL6551203 | 0.79 | ESR2 (0.31) | ESR1ESR2 | |
| SCHEMBL11152583 | 0.79 | TRPA1 (0.43) | TRPA1MAPTALOX15ESR1ESR2 | |
| SCHEMBL10258979 | 0.78 | KDM4E (0.32) | — | |
| SCHEMBL11042712 | 0.78 | TRPA1 (0.39) | TRPA1MAPTALOX15ESR1ESR2 | |
| SCHEMBL4277388 | 0.78 | CYP3A4 (0.34) | MAPTALOX15CYP3A4 | |
| SCHEMBL11241178 | 0.76 | TRPA1 (0.37) | TRPA1MAPTALOX15 | |
| SCHEMBL11256166 | 0.76 | TRPA1 (0.37) | TRPA1MAPTALOX15 | |
| SCHEMBL13781114 | 0.76 | TRPA1 (0.42) | TRPA1MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1968993-B1 | NOVEL POLYUNSATURATED COMPOUNDS, METHOD FOR PREPARING SAME AND COMPOSITIONS CONTAINING SAME | FABRE PIERRE DERMO COSMETIQUE (FR) | 2012-01-11 | — | — | EP | disclosed |
| WO-2008118862-A1 | CAROTENOID ANALOGS AND DERIVATIVES FOR THE PREVENTION OF PLATELET AGGREGATION | CARDAX PHARMACEUTICALS, INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008106606-A2 | CAROTENOID ANALOGS AND DERIVATIVES IN THE TREATMENT OF PROSTATE CANCER | CARDAX PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| US-20070219383-A1 | Method for Reducing Alkyne Compuonds | BASF AKTIENGESELLSCHAFT (DE) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219383-A1 | Method for Reducing Alkyne Compuonds | C9, C1S, C5 | TRPA1 1396/4885MAPT 4742/4885ALOX15 1304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.